Toronto, Ontario – TheNewswire – June 15, 2026 - Ventripoint Diagnostics Ltd. ("Ventripoint" or the "Company"), (TSXV:VPT; OTC:VPTDF) a pioneer in advanced cardiac imaging, today announced its support for the Global Congenital Heart Disease Alliance (“GCHDA”), a newly forming industry alliance dedicated to accelerating the development, commercialization, and global adoption of congenital cardiovascular technologies.

 

GCHDA brings together industry partners, clinicians, researchers, regulators, investors, and patient communities to address the unique challenges facing innovators in congenital heart disease (CHD) - the most common birth defect in the world. Through membership and advocacy programs, multi-center research collaboration, and a convening platform of summits and innovation showcases, GCHDA aims to build a unified support ecosystem for a field that has long been fragmented.

 

The announcement comes on the heels of the World Heart Federation's World Heart Report 2026, which found that CHD now affects approximately 2% of live births globally and that the number of people living with CHD worldwide has grown to an estimated 16 million - up from 11.8 million three decades ago. The report also found that more than 90% of children in lower- and middle-income countries lack timely access to CHD care, underscoring the urgent need for the kind of cross-sector collaboration GCHDA is designed to enable.

 

"Congenital heart disease affects patients across every stage of life, from infancy through adulthood, and the technologies needed to diagnose and monitor these conditions require exactly the kind of collaborative ecosystem that GCHDA is working to build," said Joe Hostetter, Director of the CHD Program at Ventripoint Diagnostics. "With the growing CHD population and so many patients in underserved regions lacking access to timely care, we believe accurate, accessible imaging has to be part of the solution. Supporting GCHDA reflects our commitment to working alongside the broader CHD community to help close that gap."

 

Ventripoint's flagship platform, VMS+™, uses AI to transform standard 2D echocardiograms into highly accurate 3D models of all four heart chambers, bringing cMRI-level measurement accuracy to the point of care - including for patients with congenital heart conditions, where complex anatomy often makes traditional imaging difficult. By supporting GCHDA, Ventripoint aims to help connect its imaging technology with the clinicians, researchers, and patient communities working to improve outcomes for people living with CHD worldwide.

 

"We are pleased to welcome Ventripoint as a supporter of the Global Congenital Heart Disease Alliance," said Julia Friesen, Executive Director, Global Congenital Heart Disease Alliance. "We exist to bring focused attention and determined project execution to the congenital heart disease community, leveraging our resources and relationships across finance, hospitals, insurance, and the scientific community. As part of our initial efforts, we will assist in funding and placing 4 VMS+ cardiac imaging units to directly support the CHD community and expand access to advanced diagnostic care. With Ventripoint as a partner, we look forward to helping patients, families, hospitals, and research teams gain access to the technologies and resources needed to improve care and advance innovation globally."

 

Ventripoint plans to participate in GCHDA's programming, including its annual summit and innovation showcases, and looks forward to collaborating with fellow members of the alliance on shared research and commercial initiatives that advance care for the CHD community.

 

About Ventripoint Diagnostics Ltd.

 

Ventripoint Diagnostics Ltd. (TSXV: VPT, OTCQB: VPTDF) is dedicated to improving diagnostic imaging through tools that offer higher performance, lower cost, faster turnaround, and greater patient comfort. Its flagship product, VMS+™, enhances standard echocardiography to deliver cMRI-level accuracy for volumetric measurements and ejection fractions across all four chambers of the heart, supporting applications including congenital heart disease, pulmonary hypertension, and cardiotoxicity monitoring in oncology patients. For more information, visit www.ventripoint.com.

 

About the Global Congenital Heart Disease Alliance (GCHDA)

 

The Global Congenital Heart Disease Alliance is a hybrid industry association and innovation consortium uniting industry, clinicians, researchers, regulators, and investors to accelerate the next generation of congenital cardiovascular technologies. Through membership, advocacy, shared research, and a convening platform of summits and forums, GCHDA works to transform promising ideas into accessible solutions for patients living with congenital heart disease. For more information, visit gchda.com.

 

About Ventripoint Diagnostics Ltd.

 

Ventripoint has become an industry leader in the application of AI (Artificial Intelligence) to echocardiography. Ventripoint's VMS products are powered by its proprietary Knowledge Based Reconstruction technology, which is the result of a decade of development and provides accurate volumetric cardiac measurements equivalent to MRI. This affordable, gold-standard alternative allows cardiologists greater confidence in the management of their patients. Providing better care to patients serves as a springboard and basic standard for all of Ventripoint's products that guide our future developments. In addition, VMS+ is versatile and can be used with all ultrasound systems from any vendor supported by regulatory market approvals in the U.S., Europe and Canada.

 

For further information, please contact:

 

Hugh MacNaught

hmacnaught@ventripoint.com

(604) 671-4201

 

Neither the TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this news release.

 

About Ventripoint Diagnostics Ltd.

 

Ventripoint has become an industry leader in the application of AI (Artificial Intelligence) to echocardiography. Ventripoint's VMS products are powered by its proprietary KBR technology, which is the result of a decade of development and provides accurate volumetric cardiac measurements equivalent to MRI. This affordable, gold-standard alternative allows cardiologists greater confidence in the management of their patients. Providing better care to patients serves as a springboard and basic standard for all Ventripoint's products that guide our future developments. In addition, VMS+ is versatile and can be used with all ultrasound systems from any vendor supported by regulatory market approvals in the U.S., Europe and Canada.

  

Forward Looking Statements

This news release contains forward-looking statements and forward-looking information within the meaning of applicable securities laws. The use of any of the words "expect", "anticipate", "continue", "estimate", "objective", "ongoing", "may", "will", "project", "should", "believe", "plans", "intends'' and similar expressions are intended to identify forward-looking information or statements. The forward-looking statements and information are based on certain key expectations and assumptions made by the Company. Although the Company believes that the expectations and assumptions on which such forward-looking statements and information are based are reasonable, undue reliance should not be placed on the forward-looking statements and information because the Company can give no assurance that they will prove to be correct.

Since forward-looking statements and information address future events and conditions, by their very nature they involve inherent risks and uncertainties. Actual results could differ materially from those currently anticipated due to several factors and risks. Factors which could materially affect such forward-looking information are described in the risk factors in the Company's most recent annual management's discussion and analysis that is available on the Company's profile on SEDAR at www.sedar.com. Readers are cautioned that the foregoing list of factors is not exhaustive. The forward-looking statements included in this news release are expressly qualified by this cautionary statement. The forward-looking statements and information contained in this news release are made as of the date hereof and the Company undertakes no obligation to update publicly or revise any forward-looking statements or information, whether because of new information, future events or otherwise, unless so required by applicable securities laws.